<span style="margin-left: 0em;">chemotherapy</span> <span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">placebo plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-CTLA-4</span> <span style="margin-left: 2em;">ipilimumab based treatment</span> <span style="margin-left: 3em;">ipilimumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 4em;">Ipilimumab (10 mg/kg) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">ipilimumab plus gp100 <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">ipilimumab plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">nivolumab based treatment</span> <span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab alone</span> <span style="margin-left: 4em;">pembrolizumab (10mg/kg) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 4em;">pembrolizumab (10mg/kg) 2 weeks <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 4em;">pembrolizumab (2mg/kg) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">Immunostimulant</span> <span style="margin-left: 1em;">vaccine</span> <span style="margin-left: 2em;">gp100 <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (10) progression or deaths (PFS) (10) objective responses (ORR) (10) DOR (9) deaths (OS) (extension) (3) DCR (2) PFS (extension) (2) TRAE (any grade) (10) TRAE (grade 3-4) (10) TRAE leading to discontinuation (grade 3-4) (6) TRAE leading to death (grade 5) (6) TRAE leading to discontinuation (any grade) (6) AE (any grade) (5) AE (grade 3-4) (5) AE leading to death (grade 5) (2) STRAE (any grade) (2) STRAE (grade 3-4) (2) AE leading to treatment discontinuation (any grade) (1) AE leading to treatment discontinuation (grade 3-4) (1) Diarrhoea TRAE (grade 3-4) (11) Hypothyroidism TRAE (grade 3-4) (10) Pruritus TRAE (grade 3-4) (10) Rash TRAE (grade 3-4) (10) Colitis TRAE (grade 3-4) (10) Hepatitis TRAE (grade 3-4) (10) Increased ALT TRAE (grade 3-4) (8) Increase AST TRAE (grade 3-4) (8) Hypophysitis TRAE (grade 3-4) (8) Maculopapular rash TRAE (grade 3-4) (6) Hyperthyroidism TRAE (grade 3-4) (6) Vitiligo TRAE (grade 3-4) (6) Pneumonitis TRAE (grade 3-4) (6) Anaemia TRAE (grade 3-4) (5) Arthralgia TRAE (grade 3-4) (5) Uveitis TRAE (grade 3-4) (5) Fatigue TRAE (grade 3-4) (5) Nausea TRAE (grade 3-4) (5) Decreased appetite TRAE (grade 3-4) (5) Dry skin TRAE (grade 3-4) (5) Asthenia TRAE (grade 3-4) (5) Constipation TRAE (grade 3-4) (4) Paraesthesia TRAE (grade 3-4) (4) Alopecia TRAE (grade 3-4) (4) Myalgia TRAE (grade 3-4) (4) Adrenal insufficiency TRAE (grade 3-4) (4) Skin and subcutaneous tissue disorders TRAE (grade 3-4) (4) Gastrointestinal disorders TRAE (grade 3-4) (4) Endocrine disorders TRAE (grade 3-4) (4) Neutropenia TRAE (grade 3-4) (4) Pruritic rash TRAE (grade 3-4) (4) Vomiting TRAE (grade 3-4) (4) Pancreatitis TRAE (grade 3-4) (3) Hepatobiliary disorders TRAE (grade 3-4) (3) Pyrexia TRAE (grade 3-4) (3) Dyspnoea TRAE (grade 3-4) (3) Peripheral neuropathy TRAE (grade 3-4) (3) Abdominal pain TRAE (grade 3-4) (2) Thyroiditis TRAE (grade 3-4) (2) Headache TRAE (grade 3-4) (2) Chills TRAE (grade 3-4) (2) Thrombocytopenia TRAE (grade 3-4) (2) Weight decreased TRAE (grade 3-4) (2) Myositis TRAE (grade 3-4) (2) Nephritis TRAE (grade 3-4) (2) Leucopenia TRAE (grade 3-4) (2) Cough TRAE (grade 3-4) (2) Infusion-related reactions TRAE (grade 3-4) (1) Nervous system disorders TRAE (grade 3-4) (1) Guillain-Barré syndrome TRAE (grade 3-4) (1) Polymyalgia Rheumatica TRAE (grade 3-4) (1) Febrile neutropenia TRAE (grade 3-4) (1) Pancytopenia TRAE (grade 3-4) (1) Pericarditis TRAE (grade 3-4) (1) Increased lipase level TRAE (grade 3-4) (1) Eye disorders TRAE (grade 3-4) (1) Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) (1) Hypersensitivity TRAE (grade 3-4) (1) Diabetes TRAE (grade 3-4) (1) Diarrhoea AE (grade 3-4) (4) Pyrexia AE (grade 3-4) (4) Abdominal pain AE (grade 3-4) (4) Nausea AE (grade 3-4) (4) Constipation AE (grade 3-4) (4) Fatigue AE (grade 3-4) (4) Cough AE (grade 3-4) (4) Headache AE (grade 3-4) (4) Decreased appetite AE (grade 3-4) (4) Vomiting AE (grade 3-4) (4) Dyspnoea AE (grade 3-4) (4) Anaemia AE (grade 3-4) (3) Rash AE (grade 3-4) (1) Increased ALT AE (grade 3-4) (1) Increase AST AE (grade 3-4) (1) Weight decreased AE (grade 3-4) (1) Pruritus AE (grade 3-4) (1) Chills AE (grade 3-4) (1) Asthenia AE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 MDX010 Ipi vs gp100, 2010 1 Ascierto (ipi 10 vs 3 mg/kg), 2017 1 KEYNOTE-002 (2 mg/kg), 2015 1 CA184-024, 2011 1 CheckMate 037, 2015 1 KEYNOTE-006 (2 week), 2015 1 KEYNOTE-006 (3 week), 2015 1 KEYNOTE-002 (10 mg/kg), 2015 1 MDX010 Ipi plus gp100 vs gp100, 2010 1 MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 gp100 vs. ipilimumab alone
ipilimumab alone better
1.52 [1.24; 1.86] 1.52 [1.24;1.86]gp100 vs. ipilimumab alone
ipilimumab alone better
1.52 [1.24; 1.86] gp100 vs. ipilimumab plus gp100
ipilimumab plus gp100 better
1.47 [1.22; 1.76] 1.47 [1.22;1.76]gp100 vs. ipilimumab plus gp100
ipilimumab plus gp100 better
1.47 [1.22; 1.76] gp100 vs. ipilimumab plus SoC
ipilimumab plus SoC better
2.27 [1.41; 3.63] 2.27 [1.41;3.63]gp100 vs. ipilimumab plus SoC
ipilimumab plus SoC better
2.27 [1.41; 3.63] gp100 vs. nivolumab alone
nivolumab alone better
1.72 [1.04; 2.84] 1.72 [1.04;2.84]gp100 vs. nivolumab alone
nivolumab alone better
1.72 [1.04; 2.84] gp100 vs. pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) better
2.20 [1.57; 3.10] 2.20 [1.57;3.10]gp100 vs. pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) better
2.20 [1.57; 3.10] gp100 vs. pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (10mg/kg) 2 weeks better
2.41 [1.70; 3.42] 2.41 [1.70;3.42]gp100 vs. pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (10mg/kg) 2 weeks better
2.41 [1.70; 3.42] gp100 vs. pembrolizumab (2mg/kg)
pembrolizumab (2mg/kg) better
1.90 [1.16; 3.11] 1.90 [1.16;3.11]gp100 vs. pembrolizumab (2mg/kg)
pembrolizumab (2mg/kg) better
1.90 [1.16; 3.11] gp100 vs. Standard of Care (SoC)
Standard of Care (SoC) better
1.63 [1.06; 2.51] 1.63 [1.06;2.51]gp100 vs. Standard of Care (SoC)
Standard of Care (SoC) better
1.63 [1.06; 2.51] ipilimumab alone vs. gp100
ipilimumab alone better
0.66 [0.54; 0.81] 0.66 [0.54;0.81]ipilimumab alone vs. gp100
ipilimumab alone better
0.66 [0.54; 0.81] ipilimumab alone vs. ipilimumab plus gp100
0.96 [0.80; 1.16] 0.96 [0.80;1.16]ipilimumab alone vs. ipilimumab plus gp100
0.96 [0.80; 1.16] ipilimumab alone vs. ipilimumab plus SoC
1.49 [0.97; 2.28] 1.49 [0.97;2.28]ipilimumab alone vs. ipilimumab plus SoC
1.49 [0.97; 2.28] ipilimumab alone vs. nivolumab alone
1.13 [0.71; 1.79] 1.13 [0.71;1.79]ipilimumab alone vs. nivolumab alone
1.13 [0.71; 1.79] ipilimumab alone vs. pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) better
1.45 [1.10; 1.91] 1.45 [1.10;1.91]ipilimumab alone vs. pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) better
1.45 [1.10; 1.91] ipilimumab alone vs. pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (10mg/kg) 2 weeks better
1.59 [1.19; 2.11] 1.59 [1.19;2.11]ipilimumab alone vs. pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (10mg/kg) 2 weeks better
1.59 [1.19; 2.11] ipilimumab alone vs. pembrolizumab (2mg/kg)
1.25 [0.79; 1.96] 1.25 [0.79;1.96]ipilimumab alone vs. pembrolizumab (2mg/kg)
1.25 [0.79; 1.96] ipilimumab alone vs. Standard of Care (SoC)
1.07 [0.73; 1.57] 1.07 [0.73;1.57]ipilimumab alone vs. Standard of Care (SoC)
1.07 [0.73; 1.57] ipilimumab plus gp100 vs. gp100
ipilimumab plus gp100 better
0.68 [0.57; 0.82] 0.68 [0.57;0.82]ipilimumab plus gp100 vs. gp100
ipilimumab plus gp100 better
0.68 [0.57; 0.82] ipilimumab plus gp100 vs. ipilimumab alone
1.04 [0.86; 1.25] 1.04 [0.86;1.25]ipilimumab plus gp100 vs. ipilimumab alone
1.04 [0.86; 1.25] ipilimumab plus gp100 vs. ipilimumab plus SoC
1.54 [0.97; 2.46] 1.54 [0.97;2.46]ipilimumab plus gp100 vs. ipilimumab plus SoC
1.54 [0.97; 2.46] ipilimumab plus gp100 vs. nivolumab alone
1.17 [0.71; 1.93] 1.17 [0.71;1.93]ipilimumab plus gp100 vs. nivolumab alone
1.17 [0.71; 1.93] ipilimumab plus gp100 vs. pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) better
1.50 [1.08; 2.10] 1.50 [1.08;2.10]ipilimumab plus gp100 vs. pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) better
1.50 [1.08; 2.10] ipilimumab plus gp100 vs. pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (10mg/kg) 2 weeks better
1.65 [1.17; 2.31] 1.65 [1.17;2.31]ipilimumab plus gp100 vs. pembrolizumab (10mg/kg) 2 weeks
pembrolizumab (10mg/kg) 2 weeks better
1.65 [1.17; 2.31] ipilimumab plus gp100 vs. pembrolizumab (2mg/kg)
1.29 [0.79; 2.11] 1.29 [0.79;2.11]ipilimumab plus gp100 vs. pembrolizumab (2mg/kg)
1.29 [0.79; 2.11] ipilimumab plus gp100 vs. Standard of Care (SoC)
1.11 [0.73; 1.70] 1.11 [0.73;1.70]ipilimumab plus gp100 vs. Standard of Care (SoC)
1.11 [0.73; 1.70] ipilimumab plus SoC vs. gp100
ipilimumab plus SoC better
0.44 [0.28; 0.71] 0.44 [0.28;0.71]ipilimumab plus SoC vs. gp100
ipilimumab plus SoC better
0.44 [0.28; 0.71] ipilimumab plus SoC vs. ipilimumab alone
0.67 [0.44; 1.03] 0.67 [0.44;1.03]ipilimumab plus SoC vs. ipilimumab alone
0.67 [0.44; 1.03] ipilimumab plus SoC vs. ipilimumab plus gp100
0.65 [0.41; 1.03] 0.65 [0.41;1.03]ipilimumab plus SoC vs. ipilimumab plus gp100
0.65 [0.41; 1.03] ipilimumab plus SoC vs. nivolumab alone
0.76 [0.55; 1.05] 0.76 [0.55;1.05]ipilimumab plus SoC vs. nivolumab alone
0.76 [0.55; 1.05] ipilimumab plus SoC vs. pembrolizumab (10mg/kg)
0.97 [0.70; 1.35] 0.97 [0.70;1.35]ipilimumab plus SoC vs. pembrolizumab (10mg/kg)
0.97 [0.70; 1.35] ipilimumab plus SoC vs. pembrolizumab (10mg/kg) 2 weeks
1.07 [0.64; 1.78] 1.07 [0.64;1.78]ipilimumab plus SoC vs. pembrolizumab (10mg/kg) 2 weeks
1.07 [0.64; 1.78] ipilimumab plus SoC vs. pembrolizumab (2mg/kg)
0.84 [0.61; 1.15] 0.84 [0.61;1.15]ipilimumab plus SoC vs. pembrolizumab (2mg/kg)
0.84 [0.61; 1.15] ipilimumab plus SoC vs. Standard of Care (SoC)
ipilimumab plus SoC better
0.72 [0.59; 0.87] 0.72 [0.59;0.87]ipilimumab plus SoC vs. Standard of Care (SoC)
ipilimumab plus SoC better
0.72 [0.59; 0.87] nivolumab alone vs. gp100
nivolumab alone better
0.58 [0.35; 0.96] 0.58 [0.35;0.96]nivolumab alone vs. gp100
nivolumab alone better
0.58 [0.35; 0.96] nivolumab alone vs. ipilimumab alone
0.89 [0.56; 1.41] 0.89 [0.56;1.41]nivolumab alone vs. ipilimumab alone
0.89 [0.56; 1.41] nivolumab alone vs. ipilimumab plus gp100
0.85 [0.52; 1.41] 0.85 [0.52;1.41]nivolumab alone vs. ipilimumab plus gp100
0.85 [0.52; 1.41] nivolumab alone vs. ipilimumab plus SoC
1.32 [0.95; 1.83] 1.32 [0.95;1.83]nivolumab alone vs. ipilimumab plus SoC
1.32 [0.95; 1.83] nivolumab alone vs. pembrolizumab (10mg/kg)
1.28 [0.89; 1.86] 1.28 [0.89;1.86]nivolumab alone vs. pembrolizumab (10mg/kg)
1.28 [0.89; 1.86] nivolumab alone vs. pembrolizumab (10mg/kg) 2 weeks
1.41 [0.82; 2.42] 1.41 [0.82;2.42]nivolumab alone vs. pembrolizumab (10mg/kg) 2 weeks
1.41 [0.82; 2.42] nivolumab alone vs. pembrolizumab (2mg/kg)
1.10 [0.77; 1.59] 1.10 [0.77;1.59]nivolumab alone vs. pembrolizumab (2mg/kg)
1.10 [0.77; 1.59] nivolumab alone vs. Standard of Care (SoC)
0.95 [0.73; 1.24] 0.95 [0.73;1.24]nivolumab alone vs. Standard of Care (SoC)
0.95 [0.73; 1.24] pembrolizumab (10mg/kg) vs. gp100
pembrolizumab (10mg/kg) better
0.45 [0.32; 0.64] 0.45 [0.32;0.64]pembrolizumab (10mg/kg) vs. gp100
pembrolizumab (10mg/kg) better
0.45 [0.32; 0.64] pembrolizumab (10mg/kg) vs. ipilimumab alone
pembrolizumab (10mg/kg) better
0.69 [0.52; 0.91] 0.69 [0.52;0.91]pembrolizumab (10mg/kg) vs. ipilimumab alone
pembrolizumab (10mg/kg) better
0.69 [0.52; 0.91] pembrolizumab (10mg/kg) vs. ipilimumab plus gp100
pembrolizumab (10mg/kg) better
0.67 [0.48; 0.93] 0.67 [0.48;0.93]pembrolizumab (10mg/kg) vs. ipilimumab plus gp100
pembrolizumab (10mg/kg) better
0.67 [0.48; 0.93] pembrolizumab (10mg/kg) vs. ipilimumab plus SoC
1.03 [0.74; 1.42] 1.03 [0.74;1.42]pembrolizumab (10mg/kg) vs. ipilimumab plus SoC
1.03 [0.74; 1.42] pembrolizumab (10mg/kg) vs. nivolumab alone
0.78 [0.54; 1.13] 0.78 [0.54;1.13]pembrolizumab (10mg/kg) vs. nivolumab alone
0.78 [0.54; 1.13] pembrolizumab (10mg/kg) vs. pembrolizumab (10mg/kg) 2 weeks
1.10 [0.74; 1.63] 1.10 [0.74;1.63]pembrolizumab (10mg/kg) vs. pembrolizumab (10mg/kg) 2 weeks
1.10 [0.74; 1.63] pembrolizumab (10mg/kg) vs. pembrolizumab (2mg/kg)
0.86 [0.60; 1.23] 0.86 [0.60;1.23]pembrolizumab (10mg/kg) vs. pembrolizumab (2mg/kg)
0.86 [0.60; 1.23] pembrolizumab (10mg/kg) vs. Standard of Care (SoC)
pembrolizumab (10mg/kg) better
0.74 [0.57; 0.96] 0.74 [0.57;0.96]pembrolizumab (10mg/kg) vs. Standard of Care (SoC)
pembrolizumab (10mg/kg) better
0.74 [0.57; 0.96] pembrolizumab (10mg/kg) 2 weeks vs. gp100
pembrolizumab (10mg/kg) 2 weeks better
0.41 [0.29; 0.59] 0.41 [0.29;0.59]pembrolizumab (10mg/kg) 2 weeks vs. gp100
pembrolizumab (10mg/kg) 2 weeks better
0.41 [0.29; 0.59] pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone
pembrolizumab (10mg/kg) 2 weeks better
0.63 [0.47; 0.84] 0.63 [0.47;0.84]pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone
pembrolizumab (10mg/kg) 2 weeks better
0.63 [0.47; 0.84] pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab plus gp100
pembrolizumab (10mg/kg) 2 weeks better
0.61 [0.43; 0.85] 0.61 [0.43;0.85]pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab plus gp100
pembrolizumab (10mg/kg) 2 weeks better
0.61 [0.43; 0.85] pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab plus SoC
0.94 [0.56; 1.57] 0.94 [0.56;1.57]pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab plus SoC
0.94 [0.56; 1.57] pembrolizumab (10mg/kg) 2 weeks vs. nivolumab alone
0.71 [0.41; 1.22] 0.71 [0.41;1.22]pembrolizumab (10mg/kg) 2 weeks vs. nivolumab alone
0.71 [0.41; 1.22] pembrolizumab (10mg/kg) 2 weeks vs. pembrolizumab (10mg/kg)
0.91 [0.62; 1.36] 0.91 [0.62;1.36]pembrolizumab (10mg/kg) 2 weeks vs. pembrolizumab (10mg/kg)
0.91 [0.62; 1.36] pembrolizumab (10mg/kg) 2 weeks vs. pembrolizumab (2mg/kg)
0.79 [0.46; 1.34] 0.79 [0.46;1.34]pembrolizumab (10mg/kg) 2 weeks vs. pembrolizumab (2mg/kg)
0.79 [0.46; 1.34] pembrolizumab (10mg/kg) 2 weeks vs. Standard of Care (SoC)
0.68 [0.42; 1.08] 0.68 [0.42;1.08]pembrolizumab (10mg/kg) 2 weeks vs. Standard of Care (SoC)
0.68 [0.42; 1.08] pembrolizumab (2mg/kg) vs. gp100
pembrolizumab (2mg/kg) better
0.53 [0.32; 0.87] 0.53 [0.32;0.87]pembrolizumab (2mg/kg) vs. gp100
pembrolizumab (2mg/kg) better
0.53 [0.32; 0.87] pembrolizumab (2mg/kg) vs. ipilimumab alone
0.80 [0.51; 1.26] 0.80 [0.51;1.26]pembrolizumab (2mg/kg) vs. ipilimumab alone
0.80 [0.51; 1.26] pembrolizumab (2mg/kg) vs. ipilimumab plus gp100
0.77 [0.47; 1.26] 0.77 [0.47;1.26]pembrolizumab (2mg/kg) vs. ipilimumab plus gp100
0.77 [0.47; 1.26] pembrolizumab (2mg/kg) vs. ipilimumab plus SoC
1.19 [0.87; 1.64] 1.19 [0.87;1.64]pembrolizumab (2mg/kg) vs. ipilimumab plus SoC
1.19 [0.87; 1.64] pembrolizumab (2mg/kg) vs. nivolumab alone
0.91 [0.63; 1.30] 0.91 [0.63;1.30]pembrolizumab (2mg/kg) vs. nivolumab alone
0.91 [0.63; 1.30] pembrolizumab (2mg/kg) vs. pembrolizumab (10mg/kg)
1.16 [0.81; 1.67] 1.16 [0.81;1.67]pembrolizumab (2mg/kg) vs. pembrolizumab (10mg/kg)
1.16 [0.81; 1.67] pembrolizumab (2mg/kg) vs. pembrolizumab (10mg/kg) 2 weeks
1.27 [0.75; 2.17] 1.27 [0.75;2.17]pembrolizumab (2mg/kg) vs. pembrolizumab (10mg/kg) 2 weeks
1.27 [0.75; 2.17] pembrolizumab (2mg/kg) vs. Standard of Care (SoC)
0.86 [0.67; 1.10] 0.86 [0.67;1.10]pembrolizumab (2mg/kg) vs. Standard of Care (SoC)
0.86 [0.67; 1.10] Standard of Care (SoC) vs. gp100
Standard of Care (SoC) better
0.61 [0.40; 0.94] 0.61 [0.40;0.94]Standard of Care (SoC) vs. gp100
Standard of Care (SoC) better
0.61 [0.40; 0.94] Standard of Care (SoC) vs. ipilimumab alone
0.93 [0.64; 1.36] 0.93 [0.64;1.36]Standard of Care (SoC) vs. ipilimumab alone
0.93 [0.64; 1.36] Standard of Care (SoC) vs. ipilimumab plus gp100
0.90 [0.59; 1.37] 0.90 [0.59;1.37]Standard of Care (SoC) vs. ipilimumab plus gp100
0.90 [0.59; 1.37] Standard of Care (SoC) vs. ipilimumab plus SoC
ipilimumab plus SoC better
1.39 [1.14; 1.69] 1.39 [1.14;1.69]Standard of Care (SoC) vs. ipilimumab plus SoC
ipilimumab plus SoC better
1.39 [1.14; 1.69] Standard of Care (SoC) vs. nivolumab alone
1.05 [0.81; 1.37] 1.05 [0.81;1.37]Standard of Care (SoC) vs. nivolumab alone
1.05 [0.81; 1.37] Standard of Care (SoC) vs. pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) better
1.35 [1.04; 1.75] 1.35 [1.04;1.75]Standard of Care (SoC) vs. pembrolizumab (10mg/kg)
pembrolizumab (10mg/kg) better
1.35 [1.04; 1.75] Standard of Care (SoC) vs. pembrolizumab (10mg/kg) 2 weeks
1.48 [0.92; 2.38] 1.48 [0.92;2.38]Standard of Care (SoC) vs. pembrolizumab (10mg/kg) 2 weeks
1.48 [0.92; 2.38] Standard of Care (SoC) vs. pembrolizumab (2mg/kg)
1.16 [0.91; 1.49] 1.16 [0.91;1.49]Standard of Care (SoC) vs. pembrolizumab (2mg/kg)
1.16 [0.91; 1.49] Standard of Care (SoC) placebo plus SoC ipilimumab alone gp100 pembrolizumab (2mg/kg) ipilimumab plus SoC nivolumab alone Ipilimumab (10 mg/kg) pembrolizumab (10mg/kg) 2 weeks pembrolizumab (10mg/kg) ipilimumab plus gp100 direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C Standard of Care (SoC) placebo plus SoC ipilimumab alone gp100 pembrolizumab (2mg/kg) ipilimumab plus SoC nivolumab alone Ipilimumab (10 mg/kg) pembrolizumab (10mg/kg) 2 weeks pembrolizumab (10mg/kg) ipilimumab plus gp100 Standard of Care (SoC) --- NA 0.93 0.64; 1.360.61 0.40; 0.941.16 0.91; 1.491.39 1.14; 1.691.05 0.81; 1.37NA 1.48 0.92; 2.381.35 1.04; 1.750.90 0.59; 1.37placebo plus SoC NA --- NA NA NA NA NA NA NA NA NA ipilimumab alone 1.07 0.73; 1.57NA --- 0.66 0.54; 0.811.25 0.79; 1.961.49 0.97; 2.281.13 0.71; 1.79NA 1.59 1.19; 2.111.45 1.10; 1.910.96 0.80; 1.16gp100 1.63 1.06; 2.51NA 1.52 1.24; 1.86--- 1.90 1.16; 3.112.27 1.41; 3.631.72 1.04; 2.84NA 2.41 1.70; 3.422.20 1.57; 3.101.47 1.22; 1.76pembrolizumab (2mg/kg) 0.86 0.67; 1.10NA 0.80 0.51; 1.260.53 0.32; 0.87--- 1.19 0.87; 1.640.91 0.63; 1.30NA 1.27 0.75; 2.171.16 0.81; 1.670.77 0.47; 1.26ipilimumab plus SoC 0.72 0.59; 0.87NA 0.67 0.44; 1.030.44 0.28; 0.710.84 0.61; 1.15--- 0.76 0.55; 1.05NA 1.07 0.64; 1.780.97 0.70; 1.350.65 0.41; 1.03nivolumab alone 0.95 0.73; 1.24NA 0.89 0.56; 1.410.58 0.35; 0.961.10 0.77; 1.591.32 0.95; 1.83--- NA 1.41 0.82; 2.421.28 0.89; 1.860.85 0.52; 1.41Ipilimumab (10 mg/kg) NA NA NA NA NA NA NA --- NA NA NA pembrolizumab (10mg/kg) 2 weeks 0.68 0.42; 1.08NA 0.63 0.47; 0.840.41 0.29; 0.590.79 0.46; 1.340.94 0.56; 1.570.71 0.41; 1.22NA --- 0.91 0.62; 1.360.61 0.43; 0.85pembrolizumab (10mg/kg) 0.74 0.57; 0.96NA 0.69 0.52; 0.910.45 0.32; 0.640.86 0.60; 1.231.03 0.74; 1.420.78 0.54; 1.13NA 1.10 0.74; 1.63--- 0.67 0.48; 0.93ipilimumab plus gp100 1.11 0.73; 1.70NA 1.04 0.86; 1.250.68 0.57; 0.821.29 0.79; 2.111.54 0.97; 2.461.17 0.71; 1.93NA 1.65 1.17; 2.311.50 1.08; 2.10---
pathologies: 69
- treatments: 549
result logic